XIAP and familial pancreatic carcinoma: Pamrevlumab has also been found to downregulate pro-survival factors XIAP and BIRC6 in a model of pancreatic cancer [60] and the related inhibitor of apoptosis BIRC5 was among the RT-elevated, pamrevlumab-diminished genes identified in the current model (Additional file 3: Table S3).